Anlon Healthcare Ltd

Anlon Healthcare Limited was originally incorporated as 'Anlon Ventures Private Limited', dated November 19, 2013 with the RoC. The Company changed the name to 'Anlon Healthcare Private Limited' dated May 27, 2015 issued by the RoC and further beame a Public Company named 'Anlon Healthcare Limited' dated September 2, 2024. ANLON an ideal API partner is research-driven company engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Bulk Drugs and advanced pharmaceutical intermediates. It specialize in manufacturing of high-purity pharmaceutical intermediates used as key starting materials for APIs and finished dosage formulations. It is among the few Indian manufacturers of products such as Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol, which are widely used in pain management and anti-inflammatory therapies which comply with the regulatory requirements of leading health authorities such as FDA, PMDA, KFDA, cGMP, WHO-GMP. In addition to manufacturing of Pharma Intermediate and APIs in accordance with various domestic and international standards, the Company has recently started undertaking custom manufacturing services for complex or novel chemical compounds. The Company started commercial production of Pharma Intermediate and API in 2018. It work out manufacturing activities at Rajkot, Gujarat, which comprise of two separate manufacturing blocks for manufacturing of Pharmaceutical Intermediate and APIs respectively with an aggregate installed production capacity of 400 MTPA. The Company launched the Initial Public Offering of 1,33,00,000 equity shares having the face value of Rs 10, by raising funds aggregating to Rs 121.03 Cr via fresh issue on 29 August, 2025. The Company acquired 67.48% equity shareholding in Apiqo Organics Private Limited and become subsidiary of the company w.e.f. January 09, 2026. It further acquired 56.67% equity shareholding in Bizotic Life Science Private Limited and become subsidiary of the company w.e.f. March 20, 2026.